Drug news

Nexavar (Bayer) success in Phase III trial for Thyroid Cancer

Read time: 1 mins

Last updated:5th Jan 2013

Published:5th Jan 2013

Source: Pharmawand

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Phase III trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated Thyroid Cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting.

Learning Zone Homepage

Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

Discover assorted resources and expert opinions on molecular diagnostics for RET inhibition in non-small cell lung cancer (NSCLC) and thyroid cancers.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

European Commission approves Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age

The European Commission has expanded the approval of Takhzyro (lanadelumab) to include children with hereditary angioedema (HAE) as young as 2 years of age

1 mins

Drug news

Medtronic launches Penditure LAA exclusion system in the United States

Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures

1 min

Drug news

Positive results from DREAMM-7 head-to-head phase III trial for Blenrep (belantamab mafodotin) in relapsed/refractory multiple myeloma

GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma

1 min

See all news